Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
A diagnosis of the rare, incurable blood cancer elicits questions about who, what, why in multiple myeloma? Though I’m not too enthusiastic about writing blog posts filled with statistics, I understand that I need to provide basic inform about MM on occasion.
The WebMD article linked below is helpful in providing basic statistical information about MM. Unfortunately, the article provides information while not confronting an issue that is central to managing your MM. And that is:
The cure vs. control argument, posed by an MM specialist from the Mayo Clinic in Rochester, MN, Vincent Rajkumar, simply offers two approaches to managing MM-
If you are wondering about potentially curative therapies even though no one has ever been cured of MM with toxic therapy, you get a gold star. It’s important to note that the MM specialist who achieves the longest 3, 5, and 10 year survival rates, James Berenson M.D. practices a low-dose approach to managing his MM patients.
In my experience, the cure vs. control issue is closely related to the stage 1 vs. stage 2,3 issue in that by applying a control or low-dose approach to MM treatment, young, healthy, early stage patients would live a longer, higher quality of life existence than they would by following the FDA standard-of-care therapy plan of “potentially curative” dosing.
The last issue is based on my own experience both as a long-term MM survivor and as one who has been studying and working with fellow MM survivors for years. In my experience MM patients who manage their health through:
are healthier and better able to withstand the rigors of chemotherapy year in, year out. Even low-dose chemotherapy.
If you are a mm survivor and would like to learn more about evidence-based non-conventional MM therapies email me at David.PeopleBeatingCancer@gmail.com
Thank you,
Multiple myeloma is the second most commonly diagnosed type of blood cancer (after lymphoma). But it’s still relatively uncommon. Around the world, there were about 180,000 new cases in 2022. That makes up less than 1% of all cancer diagnoses.
Cases of multiple myeloma have risen in recent decades in Australia, Western Europe, the United States, and Canada.
The 5-year relative survival rate is almost 58%, up from 23.7% in 1976. This means about 58 out of every 100 people with multiple myeloma will live 5 or more years after being diagnosed…
The 5-year survival rate for stage 1 patients is 79%.
How long you survive depends on:
Today, about 179,063 people in the U.S. live with or are in remission from myeloma…
Those who are most at risk include:
Only 4% of people are diagnosed at an early stage of myeloma. 96% of NDMM patients are stage 2,3.
When you’re 65 or older, signs and symptoms of myeloma can show up in many ways, including: